Cancer Supportive Care Drugs Market is estimated to be US$ 26.5 billion by 2032; Growing Prevalence of Cancer Diseases Fuel Market Growth

Cancer Supportive Care Drugs Market focuses on providing appropriate care and treatment to the patients suffering from various types of cancer disease as well as curing the side effects and the symptoms of cancer.

The increasing prevalence of cancer diseases and the side effects caused due to the treatments provided are the major key factor towards the growth of the target Market. The growing awareness of adverse effects of Chemotherapy and ability to lower the side-effects by help of supportive drugs by providing protection of healthy cells is likely to propel market growth. The rising progression of lung and breast cancer across the world and the requirements to manage them effectively are some factors which are expected to increase the demand for growth of the Cancer Supportive Care Drugs market.

The report “Cancer Supportive Care Drugs Market, By Therapeutic Class (G-CSFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis-Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Nonsteroidal Anti-Inflammatory Drug), And Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2032”

Key Highlights:

• In 2015 (PubMed Central), a Cancer Supportive Drug named – “Rolapitant” (Varubi tablets, Tesaro) was approved in combination with other Antiemetic agents for adults; to prevent delayed nauseatic symptoms brought by the repeated courses of emetogenic cancer chemotherapy. The advised dosage was 180 mg administered around one to two hours prior to chemotherapy on the first day.

Analyst View:

The key factor driving the growth of the Cancer Supportive Care Drugs Market is the growing prevalence of cancer diseases and the diseases caused by the treatments of cancer. Government aided organizations along with some other organizations are also contributing towards the growth of the target market. The constant increase of healthcare expenditures as well as the increasing demand of anti-cancer drugs and biosimilars is an additional boost towards the growth of the Cancer Supportive Care Drugs Market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Cancer Supportive Care Drugs Market, By Therapeutic Class (G-CSFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis-Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Nonsteroidal Anti-Inflammatory Drug), And Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2032”

Key Market Insights from the report:

Cancer Supportive Care Drugs Market accounted for US$ 20.96 billion in 2022 and is estimated to be US$ 26.5 billion by 2032 and is anticipated to register a CAGR of 2.4%. The Cancer Supportive Care Drugs Market is segmented based on Therapeutic Class, and by Region.

• Based on Therapeutic Class, Cancer Supportive Care Drugs Market can be classified into G-CFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Non-Steroidal Anti-Inflammatory Drug) and others.
• By Region, Cancer Supportive Care Drugs Market is segmented into North America, Europe, Asian pacific, Latin America and Middle East and Africa.

Competitive Landscape & their strategies of Cancer Supportive Care Drugs Market:

The key players operating in the Cancer Supportive Care Drugs Market includes, Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck and Co., Inc., Helsinn Healthcare SA, and Heron Therapeutics.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com